The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.
4hon MSN
Targeting tumor supporting cells: Lipid nanoparticles advance CAR T success in pancreatic cancer
Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...
New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by ...
A cell-based immunotherapy designed to treat rare and aggressive types of blood cancer has been granted Breakthrough Therapy ...
Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...
Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...
RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r ...
UCLA researchers developed a human stem cell-derived cell therapy for an aggressive type of breast cancer. This study focused ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
FDA grants Breakthrough Therapy status to WashU-developed off-the-shelf CAR-T cell treatment WU-CART-007 for aggressive T-cell leukemias and lymphomas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results